Latest News

Vaginal estrogen not recommended with aromatase inhibitors

Publish date: October 24, 2022

 

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Switching to fulvestrant + palbociclib benefits ER + HER2− BC patients with rising bESR1mut
Breast Cancer ICYMI
Metastatic TNBC: Apatinib + vinorelbine shows acceptable efficacy and safety in phase 2
Breast Cancer ICYMI
HER2+ metastatic BC: Dual blockade with P + T effective and safe in routine clinical practice
Breast Cancer ICYMI
Differential prognosis of germline BRCA1/2 mutations according to tumor subtypes
Breast Cancer ICYMI
Re-BCS may not be the best strategy in ipsilateral breast tumor recurrence
Breast Cancer ICYMI
pT1a-b ER+ BC: Endocrine therapy benefits patients with grade 2-3 tumors
Breast Cancer ICYMI
Risk for second primary colorectal, pancreatic, and thyroid cancers elevated in male BC survivors
Breast Cancer ICYMI
Contraceptive use during and after BC diagnosis in premenopausal women
Breast Cancer ICYMI
Risk for persistent sedative-hypnotic use among patients receiving adjuvant chemotherapy
Breast Cancer ICYMI
High IL-6 and CRP levels predict chemotherapy-induced clinical decline in older BC patients
Breast Cancer ICYMI